Testing for HER2 in Breast Cancer: A Continuing Evolution.
about
Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.Inhibition of Cell Growth and Induction of Apoptosis by Antrodia camphorata in HER-2/neu-Overexpressing Breast Cancer Cells through the Induction of ROS, Depletion of HER-2/neu, and Disruption of the PI3K/Akt Signaling Pathway.The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathwaysA gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer.Inhibition of cell growth by BrMC through inactivation of Akt in HER-2/neu-overexpressing breast cancer cells.Breast cancer biomarker measurements and standards.C-erbB2/HER2 in human gliomas, medulloblastomas, and meningiomas: a minireview.Computer Aided Semi-Automated Evaluation of HER2 Immunodetection--A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy.Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.Disposable inkjet-printed electrochemical platform for detection of clinically relevant HER-2 breast cancer biomarker.Fluorescent in Situ Hybridization and Real-Time Quantitative Polymerase Chain Reaction to Evaluate HER-2/neu Status in Breast Cancer.
P2860
Q35038694-B5A768C7-0184-42CE-9A0A-18496421F4D8Q36022060-33BE49BD-FA39-4A63-B675-04DC7015257FQ36355817-D2B36881-CB58-4524-802A-A4FDED8DB509Q36367606-B4DF40C7-8A8F-43A3-A48C-68EEABB2B357Q36649356-8D007EE1-2C36-454B-9270-7466F57F1D05Q36903218-4E4A8F8D-0379-4726-87B5-93312700497CQ37720036-8D361840-9AB7-43C7-B71A-94CD3B7E304EQ38076082-D5922994-F265-41E5-A701-8F489FFCF5C2Q38120594-11F3096B-FFF3-422A-A779-F5F5B03DC813Q40264759-7E75E30E-A55B-4BA1-BC61-7816A5BF081EQ47938353-8D6D7F01-5E4E-470D-A286-91FF4EBB6FD8Q50055468-F7CF6635-8718-4CC0-B6EB-148187F8EFB1Q55129506-87BC11B1-98CF-4906-99D4-A80138D1485B
P2860
Testing for HER2 in Breast Cancer: A Continuing Evolution.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Testing for HER2 in Breast Cancer: A Continuing Evolution.
@ast
Testing for HER2 in Breast Cancer: A Continuing Evolution.
@en
Testing for HER2 in Breast Cancer: A Continuing Evolution.
@nl
type
label
Testing for HER2 in Breast Cancer: A Continuing Evolution.
@ast
Testing for HER2 in Breast Cancer: A Continuing Evolution.
@en
Testing for HER2 in Breast Cancer: A Continuing Evolution.
@nl
prefLabel
Testing for HER2 in Breast Cancer: A Continuing Evolution.
@ast
Testing for HER2 in Breast Cancer: A Continuing Evolution.
@en
Testing for HER2 in Breast Cancer: A Continuing Evolution.
@nl
P2860
P356
P1476
Testing for HER2 in Breast Cancer: A Continuing Evolution.
@en
P2093
Beiyun Chen
Sejal Shah
P2860
P304
P356
10.4061/2011/903202
P577
2010-12-06T00:00:00Z